Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + anlotinib + albumin paclitaxel for previously treated extensive-stage small cell lung cancer
ChiCTR2100049390Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Jun 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, anlotinib and paclitaxel in small cell lung cancer (SCLC), sponsored by Shandong Cancer Hospital. Primary endpoint: objective response rate. Planned start Jun 2021; status: not yet recruiting.
02
Drugs
sintilimabanlotinibpaclitaxel
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2100049390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049390.